Loading...
XSHG603233
Market cap2.44bUSD
Dec 27, Last price  
15.67CNY
1D
0.00%
1Q
5.81%
IPO
7.87%
Name

DaShenLin Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHG:603233 chart
P/E
15.27
P/S
0.73
EPS
1.03
Div Yield, %
3.20%
Shrs. gr., 5y
0.94%
Rev. gr., 5y
22.59%
Revenues
24.53b
+15.45%
3,252,460,2263,706,656,0744,545,011,0075,265,481,8596,273,722,0227,421,196,9038,859,273,70811,141,165,08214,582,865,28216,759,335,26421,248,086,69224,531,390,152
Net income
1.17b
+12.63%
149,183,213197,382,181265,501,554395,434,058430,188,669474,960,964531,633,897702,661,9611,062,181,101791,230,9801,035,723,8341,166,498,182
CFO
3.17b
-15.51%
289,310,273288,219,956448,578,297468,587,221495,601,186640,388,127873,639,8441,707,770,7071,953,915,8281,554,994,8633,756,573,4353,173,848,332
Dividend
Jun 21, 20240.31 CNY/sh
Earnings
May 20, 2025

Profile

DaShenLin Pharmaceutical Group Co., Ltd. manufactures, wholesales, and retails pharmaceutical products in China. The company was founded in 1999 and is based in Guangzhou, China.
URL
http://www.dslyy.com/
IPO date
Jul 31, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
24,531,390
15.45%
21,248,087
26.78%
16,759,335
14.92%
Cost of revenue
21,762,645
18,760,207
14,960,568
Unusual Expense (Income)
NOPBT
2,768,745
2,487,880
1,798,767
NOPBT Margin
11.29%
11.71%
10.73%
Operating Taxes
397,124
335,621
239,518
Tax Rate
14.34%
13.49%
13.32%
NOPAT
2,371,621
2,152,259
1,559,249
Net income
1,166,498
12.63%
1,035,724
30.90%
791,231
-25.51%
Dividends
(569,451)
(395,465)
(526,897)
Dividend yield
2.02%
1.05%
1.59%
Proceeds from repurchase of equity
(946)
12,818
BB yield
0.00%
-0.04%
Debt
Debt current
759,733
1,679,616
1,071,026
Long-term debt
7,777,698
7,041,594
7,156,005
Deferred revenue
17,642
20,122
Other long-term liabilities
28,967
328
(1,252,149)
Net debt
3,923,510
4,095,998
5,284,502
Cash flow
Cash from operating activities
3,173,848
3,756,573
1,554,995
CAPEX
(1,796,641)
Cash from investing activities
(1,986,828)
Cash from financing activities
(1,968,637)
FCF
1,123,651
1,710,991
(2,807,298)
Balance
Cash
4,458,334
4,585,039
2,901,731
Long term investments
155,587
40,172
40,799
Excess cash
3,387,352
3,562,807
2,104,563
Stockholders' equity
5,931,918
5,488,909
4,414,316
Invested Capital
10,042,122
9,006,276
7,707,825
ROIC
24.90%
25.75%
28.72%
ROCE
20.62%
19.79%
16.26%
EV
Common stock shares outstanding
1,132,523
1,136,103
1,135,532
Price
24.90
-24.55%
33.00
12.85%
29.24
-35.50%
Market cap
28,199,810
-24.78%
37,491,413
12.90%
33,206,424
-35.36%
EV
33,232,552
42,239,681
38,948,226
EBITDA
4,464,636
3,775,997
2,947,951
EV/EBITDA
7.44
11.19
13.21
Interest
275,338
48,235
212,043
Interest/NOPBT
9.94%
1.94%
11.79%